PIK3CA and colorectal cancer: The present study found that patients in the PI3K/Akt-MT group of the immunotherapy cohort had a higher frequency of mutations in the PIK3CA gene, which suggests that PIK3CA mutations may improve the prognosis of colorectal cancer patients receiving ICI therapy.